Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in The Netherlands

20245 citationsJournal Articlehybrid Open Access

Authors

Aernoud T.L. Fiolet · University Medical Center Utrecht

Willem R. Keusters · Dutch Healthcare Authority

Johan Blokzijl · Utrecht University

Stefan M. Nidorf · Genesis HealthCare

John W. Eikelboom · McMaster University

Charley Budgeon · The University of Western Australia

Jan G.P. Tijssen

Abstract

Adding low-dose colchicine to standard of care in patients with chronic coronary disease is cost-effective according to commonly accepted thresholds in Europe and Australia and compares favourably in cost-effectiveness to other drugs used in chronic coronary disease.

Topics & Keywords

Lipoproteins and Cardiovascular Health Inflammasome and immune disorders Biomarkers in Disease Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal - Quality of Care and Clinical Outcomes

Volume 11, Issue 1, pp. 89-96

DOI: 10.1093/ehjqcco/qcae021

Field-Weighted Citation Impact: 2.83